The Quantellect read.As of Nov 19, 2026, 4 active firms cover Encompass Health Corp: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $140.00 to $155.00, so the covering firms are broadly aligned. The average target of $147.25 sits 9% above the current $134.93. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.70 next quarter toward $6.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$147.25
+9.1% upside
Average target across 4 active firms as of Nov 19, 2026 vs $134.93 current
Highest Target$155.00
Average Target$147.25
Lowest Target$140.00
Detailed analyst forecasts for EHC
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate EHC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EHC EPS & revenue forecast
EPS · NEXT QUARTER
$1.70
Range $1.61 – $1.75 · 8 analysts · +6% YoY
Next period, 8 analysts expect Encompass Health Corp to earn $1.70 a share (range $1.61 – $1.75), versus $1.60 a year earlier. Full-year consensus is $6.28, growing to $6.89 the year after.
REVENUE · NEXT QUARTER
$1.7B
Range $1.7B – $1.7B · 8 analysts · +8% YoY
Revenue is expected to reach $1.7B (range $1.7B – $1.7B), +8.0% year-over-year. Full-year consensus is $6.5B, rising to $7.0B next year.
Top analysts covering Encompass Health Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EHC.
#1
DM
David Macdonald
Truist Securities · Rank #111
Buy
$150.00+11.2% to target
Overall win rate
50%
+ Follow
#2
Ben Hendrix
RBC Capital · Rank #150
Buy
$125.00-7.4% to target
Overall win rate
44%
+ Follow
#3
Brian Tanquilut
Jefferies · Rank #280
Buy
$130.00-3.7% to target
Overall win rate
46%
+ Follow
#4
AR
A.J. Rice
UBS · Rank #365
Buy
$155.00+14.9% to target
Overall win rate
35%
+ Follow
#5
Andrew Mok
Barclays · Rank #385
Buy
$144.00+6.7% to target
Overall win rate
39%
+ Follow
EHC stock forecast FAQ
What is EHC's average 12-month price target?+
The 4 active firms with a live target average $147.25 for Encompass Health Corp over the next 12 months, ranging from a $155.00 high to a $140.00 low, as of Nov 19, 2026.
Is EHC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EHC?+
The Street-high target is $155.00 (UBS), and the Street-low is $140.00 (TD Cowen). The average of all 4 active-firm targets is $147.25.
How many active Wall Street firms cover EHC?+
4 active firms have a recognized rating on Encompass Health Corp as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EHC?+
Among analysts who currently cover EHC, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Buy with a $150.00 target.
What is Encompass Health Corp's projected EPS for next quarter?+
The consensus estimate is $1.70 per share (range $1.61 – $1.75) across 8 analysts. Full-year EPS is projected at $6.28, rising to $6.89 the following year.
How much revenue is Encompass Health Corp expected to report next quarter?+
Consensus revenue is $1.7B (range $1.7B – $1.7B). Full-year revenue is projected at $6.5B, growing to $7.0B next year.
Have analysts been upgrading or downgrading EHC lately?+
As of Nov 19, 2026, 4 of 4 active firms rate EHC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.